Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion type Assertion NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_head.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion description "[In contingent screening, a detection rate of 98% for trisomy 21 and 96% for trisomy 18 or 13, at an invasive testing rate of 0.7%, can be achieved by carrying out cfDNA testing in about 35, 20 and 11% of cases identified by first-line screening with the combined test alone (age, NT, FHR, ?-hCG, PAPP-A), the combined test plus PLGF and AFP and the combined test plus PLGF, AFP and DV PIV, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_provenance.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion evidence source_evidence_literature NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_provenance.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion SIO_000772 24192489 NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_provenance.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion wasDerivedFrom befree-2016 NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_provenance.
- NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_assertion wasGeneratedBy ECO_0000203 NP1125140.RAXoUTxrdZKPJbszgbiIkG6FbLEBG6fl19BsI72Unvfbw130_provenance.